New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure

Giuseppe Campiani, Vito Nacci, Susanna Bechelli, Silvia M. Ciani, Antonio Garofalo, Isabella Fiorini, Håkan Wikström, Peter De Boer, Yi Liao, Pieter G. Tepper, Alfredo Cagnotto, Tiziana Mennini

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

The development of a synthetic approach to the novel pyrrolo[2,1- b][1,3]benzothiazepine and its derivatives and their biological evaluation as potential antipsychotic drugs are described. In binding studies these compounds proved to be potent 5-HT2, D2, and D3 receptor ligands. The more potent benzothiazepine (±)-3b was resolved into its enantiomers by using HPLC techniques. In vitro testing confirmed that (-)-3b is a more potent D2 receptor ligand, maintaining high affinity for 5-HT2 receptors. In contrast, the (+)-3b enantiomer presents a 35 times higher affinity for 5-HT2 than for dopamine D2 receptors with a similar dopamine D1 receptor affinity to that of (-)-3b. Overall, (+)-3b shows an 'atypical' neuroleptic binding profile, while (-)-3b has a more 'classical' profile. Furthermore pharmacological and biochemical testing displayed that the novel benzothiazepine (±)-3b is able to increase the extracellular levels of dopamine in the rat striatum and causes a dose-related suppression of apomorphine-induced locomotor activity. At low doses (±)-3b does not induce catalepsy, showing atypical antipsychotic properties similar to those of olanzapine. These heterocyclic compounds represent new leads for the development of novel antipsychotic drugs with atypical properties.

Original languageEnglish
Pages (from-to)3763-3772
Number of pages10
JournalJournal of Medicinal Chemistry
Volume41
Issue number20
DOIs
Publication statusPublished - Sep 24 1998

Fingerprint

Serotonin Antagonists
Dopamine Antagonists
Antipsychotic Agents
Enantiomers
olanzapine
Ligands
Heterocyclic Compounds
Catalepsy
Dopamine D1 Receptors
Dopamine D2 Receptors
Apomorphine
Testing
Locomotion
Rats
Dopamine
High Pressure Liquid Chromatography
Pharmacology
Derivatives

ASJC Scopus subject areas

  • Organic Chemistry

Cite this

New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure. / Campiani, Giuseppe; Nacci, Vito; Bechelli, Susanna; Ciani, Silvia M.; Garofalo, Antonio; Fiorini, Isabella; Wikström, Håkan; De Boer, Peter; Liao, Yi; Tepper, Pieter G.; Cagnotto, Alfredo; Mennini, Tiziana.

In: Journal of Medicinal Chemistry, Vol. 41, No. 20, 24.09.1998, p. 3763-3772.

Research output: Contribution to journalArticle

Campiani, G, Nacci, V, Bechelli, S, Ciani, SM, Garofalo, A, Fiorini, I, Wikström, H, De Boer, P, Liao, Y, Tepper, PG, Cagnotto, A & Mennini, T 1998, 'New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure', Journal of Medicinal Chemistry, vol. 41, no. 20, pp. 3763-3772. https://doi.org/10.1021/jm9706832
Campiani, Giuseppe ; Nacci, Vito ; Bechelli, Susanna ; Ciani, Silvia M. ; Garofalo, Antonio ; Fiorini, Isabella ; Wikström, Håkan ; De Boer, Peter ; Liao, Yi ; Tepper, Pieter G. ; Cagnotto, Alfredo ; Mennini, Tiziana. / New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure. In: Journal of Medicinal Chemistry. 1998 ; Vol. 41, No. 20. pp. 3763-3772.
@article{1abd6f815c8d452aac113e9ffe481192,
title = "New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure",
abstract = "The development of a synthetic approach to the novel pyrrolo[2,1- b][1,3]benzothiazepine and its derivatives and their biological evaluation as potential antipsychotic drugs are described. In binding studies these compounds proved to be potent 5-HT2, D2, and D3 receptor ligands. The more potent benzothiazepine (±)-3b was resolved into its enantiomers by using HPLC techniques. In vitro testing confirmed that (-)-3b is a more potent D2 receptor ligand, maintaining high affinity for 5-HT2 receptors. In contrast, the (+)-3b enantiomer presents a 35 times higher affinity for 5-HT2 than for dopamine D2 receptors with a similar dopamine D1 receptor affinity to that of (-)-3b. Overall, (+)-3b shows an 'atypical' neuroleptic binding profile, while (-)-3b has a more 'classical' profile. Furthermore pharmacological and biochemical testing displayed that the novel benzothiazepine (±)-3b is able to increase the extracellular levels of dopamine in the rat striatum and causes a dose-related suppression of apomorphine-induced locomotor activity. At low doses (±)-3b does not induce catalepsy, showing atypical antipsychotic properties similar to those of olanzapine. These heterocyclic compounds represent new leads for the development of novel antipsychotic drugs with atypical properties.",
author = "Giuseppe Campiani and Vito Nacci and Susanna Bechelli and Ciani, {Silvia M.} and Antonio Garofalo and Isabella Fiorini and H{\aa}kan Wikstr{\"o}m and {De Boer}, Peter and Yi Liao and Tepper, {Pieter G.} and Alfredo Cagnotto and Tiziana Mennini",
year = "1998",
month = "9",
day = "24",
doi = "10.1021/jm9706832",
language = "English",
volume = "41",
pages = "3763--3772",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "20",

}

TY - JOUR

T1 - New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure

AU - Campiani, Giuseppe

AU - Nacci, Vito

AU - Bechelli, Susanna

AU - Ciani, Silvia M.

AU - Garofalo, Antonio

AU - Fiorini, Isabella

AU - Wikström, Håkan

AU - De Boer, Peter

AU - Liao, Yi

AU - Tepper, Pieter G.

AU - Cagnotto, Alfredo

AU - Mennini, Tiziana

PY - 1998/9/24

Y1 - 1998/9/24

N2 - The development of a synthetic approach to the novel pyrrolo[2,1- b][1,3]benzothiazepine and its derivatives and their biological evaluation as potential antipsychotic drugs are described. In binding studies these compounds proved to be potent 5-HT2, D2, and D3 receptor ligands. The more potent benzothiazepine (±)-3b was resolved into its enantiomers by using HPLC techniques. In vitro testing confirmed that (-)-3b is a more potent D2 receptor ligand, maintaining high affinity for 5-HT2 receptors. In contrast, the (+)-3b enantiomer presents a 35 times higher affinity for 5-HT2 than for dopamine D2 receptors with a similar dopamine D1 receptor affinity to that of (-)-3b. Overall, (+)-3b shows an 'atypical' neuroleptic binding profile, while (-)-3b has a more 'classical' profile. Furthermore pharmacological and biochemical testing displayed that the novel benzothiazepine (±)-3b is able to increase the extracellular levels of dopamine in the rat striatum and causes a dose-related suppression of apomorphine-induced locomotor activity. At low doses (±)-3b does not induce catalepsy, showing atypical antipsychotic properties similar to those of olanzapine. These heterocyclic compounds represent new leads for the development of novel antipsychotic drugs with atypical properties.

AB - The development of a synthetic approach to the novel pyrrolo[2,1- b][1,3]benzothiazepine and its derivatives and their biological evaluation as potential antipsychotic drugs are described. In binding studies these compounds proved to be potent 5-HT2, D2, and D3 receptor ligands. The more potent benzothiazepine (±)-3b was resolved into its enantiomers by using HPLC techniques. In vitro testing confirmed that (-)-3b is a more potent D2 receptor ligand, maintaining high affinity for 5-HT2 receptors. In contrast, the (+)-3b enantiomer presents a 35 times higher affinity for 5-HT2 than for dopamine D2 receptors with a similar dopamine D1 receptor affinity to that of (-)-3b. Overall, (+)-3b shows an 'atypical' neuroleptic binding profile, while (-)-3b has a more 'classical' profile. Furthermore pharmacological and biochemical testing displayed that the novel benzothiazepine (±)-3b is able to increase the extracellular levels of dopamine in the rat striatum and causes a dose-related suppression of apomorphine-induced locomotor activity. At low doses (±)-3b does not induce catalepsy, showing atypical antipsychotic properties similar to those of olanzapine. These heterocyclic compounds represent new leads for the development of novel antipsychotic drugs with atypical properties.

UR - http://www.scopus.com/inward/record.url?scp=14444269458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14444269458&partnerID=8YFLogxK

U2 - 10.1021/jm9706832

DO - 10.1021/jm9706832

M3 - Article

VL - 41

SP - 3763

EP - 3772

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 20

ER -